Phase II study of elliptinium in metastatic soft tissue sarcoma.
A phase II study was carried out with 9-hydroxy-methyl-elliptinium (9-HME) in metastatic soft tissue sarcoma. The dose was 100 mg/m2 weekly in 1 1/2 hr intravenous infusion protected from light. Nineteen cases were evaluable for response, all previously treated with other chemotherapy regimens. No remissions were seen. Major toxicities were nausea and vomiting, dryness of the mouth and anorexia. It is concluded that 9-HME is not an effective drug in metastatic soft tissue sarcoma.
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D004341:Drug Evaluation; D004611:Ellipticines / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy / Q000556:secondary*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary*
D000470:Alkaloids; D004611:Ellipticines; C027767:elliptinium